Azilect (rasagiline mesylate) NDC 68546-142

NDC codes

FDA NDC Directory

Product NDC (as listed)68546-142Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68546-0142Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68546-142-56	68546014256	30 TABLET in 1 BOTTLE (68546-142-56)Marketed from Jul 10, 2006

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Azilect
Generic name (nonproprietary): rasagiline mesylate
Active ingredients: Rasagiline mesylate — .5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Teva Neuroscience, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 021641
Marketing start: Jul 10, 2006
Listing expires: Dec 31, 2027
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 68546-142_485881b0-fd51-4bea-8235-43efb940cd64SPL ID 485881b0-fd51-4bea-8235-43efb940cd64SPL set ID a40d0e73-3f9f-4b01-979d-402c9cdaeb60RxCUI 608328, 636664, 637185, 637218UNII LH8C2JI290
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468546014256 followed by a unit qualifier and the quantity

Package 68546-0142-56. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jun 30, 2020.

Indications (excerpt from the label)

AZILECT (rasagiline tablets) is indicated for the treatment of Parkinson’s disease (PD). AZILECT, a monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson’s disease ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 021641

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 021641
Product	Strength	Form · route	Labeler	Product NDC
Azilectrasagiline mesylate	Rasagiline mesylate 1 mg/1	TabletOral	Teva Neuroscience, Inc.	68546-229
Rasagiline	Rasagiline mesylate .5 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-3060
Rasagiline	Rasagiline mesylate 1 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-3061